{
    "root": "9501902c-545c-425d-9e47-528ed00bf543",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Doxycycline Hyclate",
    "value": "20250414",
    "ingredients": [
        {
            "name": "DOXYCYCLINE HYCLATE",
            "code": "19XTS3T51U"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)",
            "code": "87Y6436BKR"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M)",
            "code": "88X4A2YW6T"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "doxycycline hyclate delayed-release tablets tetracycline-class indicated : rickettsial infections ( 1.1 ) sexually transmitted infections ( 1.2 ) respiratory tract infections ( 1.3 ) bacterial infections ( 1.4 ) ophthalmic infections ( 1.5 ) anthrax , including inhalational anthrax ( post-exposure ) ( 1.6 ) alternative treatment selected infections penicillin contraindicated ( 1.7 ) adjunctive therapy acute intestinal amebiasis severe acne ( 1.8 ) prophylaxis malaria ( 1.9 ) usage reduce development drug-resistant bacteria maintain effectiveness doxycycline hyclate delayed-release tablets antibacterial drugs , doxycycline hyclate delayed-release tablets used treat prevent infections proven strongly suspected caused bacteria . ( 1.10 )",
    "contraindications": "adult patients : usual 200 mg first day treatment ( administered 100 mg every 12 hours ) followed maintenance dose 100 mg daily . ( 2.1 ) management severe infections ( particularly chronic infections urinary tract ) , 100 mg every 12 hours recommended . ( 2.1 ) pediatric patients : pediatric patients weighing less 45 kg severe life-threatening infections ( e.g . , anthrax , rocky mountain spotted fever ) , recommended dose 2.2 mg per kg body weight administered every 12 hours . pediatric patients weighing 45 kg receive adult dose . ( 2.1 ) pediatric patients less severe disease ( greater 8 years age weighing less 45 kg ) , recommended dose 4.4 mg per kg body weight divided two doses first day treatment , followed maintenance dose 2.2 mg per kg body weight ( given single daily dose divided two doses ) . pediatric patients weighing 45 kg , usual adult dose used . ( 2.1 )",
    "warningsAndPrecautions": "doxycycline hyclate delayed-release tablets , usp available follows : 50 mg – yellow , oval tablet debossed “ 0 ” one side plain side contains specially coated yellow brown pellets 57.7 mg doxycycline hyclate , usp equivalent 50 mg doxycycline . tablets supplied bottles 120 ( ndc 0591-4550-22 ) . 200 mg – yellow , oval , scored tablet debossed “ t|9 ” one side plain side contains specially coated yellow brown pellets 230.8 mg doxycycline hyclate , usp equivalent 200 mg doxycycline . tablets supplied bottles 60 ( ndc 0591-4575-60 ) . store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp .",
    "adverseReactions": "doxycycline hyclate delayed-release tablets contraindicated persons shown hypersensitivity tetracyclines .",
    "indications_original": "Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 )",
    "contraindications_original": "Dosage in Adult Patients : The usual dosage is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg daily. ( 2.1 ) In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended. ( 2.1 ) Dosage in Pediatric Patients : For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dose is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose. ( 2.1 ) For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dose is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into two doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used. ( 2.1 )",
    "warningsAndPrecautions_original": "Doxycycline hyclate delayed-release tablets, USP are available as follows:\n                  50 mg –   Each yellow, oval tablet debossed with “T 0” on one side and plain on the other side contains specially coated yellow to brown pellets of 57.7 mg doxycycline hyclate, USP equivalent to 50 mg of doxycycline. Tablets are supplied in bottles of 120 (NDC 0591-4550-22).\n                  200 mg – Each yellow, oval, scored tablet debossed with “T|9” on one side and plain on the other side contains specially coated yellow to brown pellets of 230.8 mg doxycycline hyclate, USP equivalent to 200 mg of doxycycline. Tablets are supplied in bottles of 60 (NDC 0591-4575-60).\n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in USP.",
    "adverseReactions_original": "Doxycycline hyclate delayed-release tablets are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines."
}